Screener
Innoviva, Inc. INVA Xacduro — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:26 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335235
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| GIAPREZA® | $22,299 | $17,329 | $42,530 | $35,602 |
| XACDURO® | 22,382 | 10,731 | 40,456 | 18,514 |
| XERAVA® | 6,739 | 7,094 | 9,367 | 11,317 |
| ZEVTERA® | 351 | 339 | 789 | 339 |
| Total net product sales | $51,771 | $35,493 | $93,142 | $65,772 |
Item 1. Financial Statements
FAQ
- What is Innoviva, Inc.'s xacduro — revenue?
- Innoviva, Inc. (INVA) reported xacduro — revenue of $22.38M in Q2 2026.
- How has Innoviva, Inc.'s xacduro — revenue changed year-over-year?
- Innoviva, Inc.'s xacduro — revenue increased by 108.6% year-over-year, from $10.73M to $22.38M.
- What does xacduro — revenue mean?
- This metric represents the total revenue generated from the sale of the Xacduro product to customers, excluding any sales-based taxes collected. It serves as a primary indicator of the product's market adoption and commercial performance within the company's infectious disease portfolio. Tracking this figure allows investors to assess the direct top-line contribution and growth trajectory of this specific therapeutic asset.
Ask your AI about Innoviva, Inc.'s xacduro — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude